Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.

Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Wittig BM, Gnann H, Greger G, Tony HP, Burkhardt H.

Scand J Rheumatol. 2019 Jul 16:1-8. doi: 10.1080/03009742.2019.1600717. [Epub ahead of print]

PMID:
31311386
2.

Pupils say more than a thousand words: Pupil size reflects how observed actions are interpreted.

Quesque F, Behrens F, Kret ME.

Cognition. 2019 Sep;190:93-98. doi: 10.1016/j.cognition.2019.04.016. Epub 2019 Apr 28.

PMID:
31034971
4.

Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants.

Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, Sticherling M, Schett G, Simon D, Mössner R, Nimeh A, Oji V, Assmann G, Rech J, Holmdahl R, Burkhardt H, Reis A, Hüffmeier U.

Rheumatology (Oxford). 2019 Feb 7. doi: 10.1093/rheumatology/key448. [Epub ahead of print] No abstract available.

PMID:
30753645
5.

The need for comparative data in spondyloarthritis.

Choy E, Baraliakos X, Behrens F, D'Angelo S, de Vlam K, Kirkham BW, Østergaard M, Schett GA, Rissler M, Chaouche-Teyara K, Perella C.

Arthritis Res Ther. 2019 Jan 22;21(1):32. doi: 10.1186/s13075-019-1812-3.

6.

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.

Mojtahed Poor S, Ulshöfer T, Gabriel LA, Henke M, Köhm M, Behrens F, Geisslinger G, Parnham MJ, Burkhardt H, Schiffmann S.

Clin Exp Immunol. 2019 May;196(2):259-275. doi: 10.1111/cei.13261. Epub 2019 Feb 3.

PMID:
30656642
8.

[Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain].

Dauth S, Köhm M, Rossmanith T, Herrmann E, Lehn A, Burkhardt H, Behrens F.

Z Rheumatol. 2018 Nov;77(9):808-814. doi: 10.1007/s00393-018-0533-3. German.

PMID:
30203153
9.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.

Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182.

10.

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab.

Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Gnann H, Greger G, Tony HP, Burkhardt H.

Rheumatology (Oxford). 2018 Nov 1;57(11):1938-1946. doi: 10.1093/rheumatology/key203.

11.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
12.

Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.

Behrens F, Meier L, Prinz JC, Jobst J, Lippe R, Löschmann PA, Lorenz HM.

J Rheumatol. 2018 Jun;45(6):802-810. doi: 10.3899/jrheum.170932. Epub 2018 Apr 1.

PMID:
29606665
13.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17.

PMID:
29343509
14.

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.

Gossec L, McGonagle D, Korotaeva T, Lubrano E, de Miguel E, Østergaard M, Behrens F.

J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15. Review.

15.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.

16.

Genome-wide association and targeted analysis of copy number variants with psoriatic arthritis in German patients.

Uebe S, Ehrlicher M, Ekici AB, Behrens F, Böhm B, Homuth G, Schurmann C, Völker U, Jünger M, Nauck M, Völzke H, Traupe H, Krawczak M, Burkhardt H, Reis A, Hüffmeier U.

BMC Med Genet. 2017 Aug 23;18(1):92. doi: 10.1186/s12881-017-0447-y.

17.

[Psoriatic arthritis : Current therapeutic standards].

Köhm M, Behrens F.

Z Rheumatol. 2017 Aug;76(6):495-503. doi: 10.1007/s00393-017-0334-0. Review. German.

PMID:
28664281
18.

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.

Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. German.

PMID:
28589389
19.

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Behrens F, Thaçi D, Wollenhaupt J, Krüger K.

Hautarzt. 2017 Feb;68(2):153-169. doi: 10.1007/s00105-016-3925-9. Review. German.

PMID:
28083597
20.

Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis.

Scharbatke EC, Behrens F, Schmalzing M, Koehm M, Greger G, Gnann H, Burkhardt H, Tony HP.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1607-1615. doi: 10.1002/acr.22884. Epub 2016 Oct 1.

21.

Trauma-related self-defining memories and future goals in Dissociative Identity Disorder.

Huntjens RJC, Wessel I, Ostafin BD, Boelen PA, Behrens F, van Minnen A.

Behav Res Ther. 2016 Dec;87:216-224. doi: 10.1016/j.brat.2016.10.002. Epub 2016 Oct 11.

PMID:
27770748
22.

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A.

Rheumatology (Oxford). 2017 May 1;56(5):689-697. doi: 10.1093/rheumatology/kew271. Review.

PMID:
27550301
23.

Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis.

Behrens F, Koehm M, Thaçi D, Gnann H, Greger G, Maria Wittig B, Burkhardt H.

Rheumatology (Oxford). 2016 Oct;55(10):1791-5. doi: 10.1093/rheumatology/kew229. Epub 2016 Jun 21.

24.

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Behrens F, Thaçi D, Wollenhaupt J, Krüger K.

Z Rheumatol. 2016 Jun;75(5):471-88. doi: 10.1007/s00393-016-0110-6. Review. German.

PMID:
27259913
25.

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.

Combe B, Behrens F, McHugh N, Brock F, Kerkmann U, Kola B, Gallo G.

J Rheumatol. 2016 Jun;43(6):1063-7. doi: 10.3899/jrheum.151290. Epub 2016 May 1.

PMID:
27134249
26.

Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients.

Löhr S, Uebe S, Behrens F, Böhm B, Köhm M, Traupe H, Oji V, Burkhardt H, Reis A, Hüffmeier U.

Br J Dermatol. 2016 Sep;175(3):639-41. doi: 10.1111/bjd.14624. Epub 2016 Jul 24. No abstract available.

PMID:
27038307
27.

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus.

Budu-Aggrey A, Bowes J, Loehr S, Uebe S, Zervou MI, Helliwell P, Ryan AW, Kane D, Korendowych E, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Behrens F, Burkhardt H, Huffmeier U, Ho P, Martin J, Castañeda S, Goulielmos G, Reis A, Barton A.

Ann Rheum Dis. 2016 Jul;75(7):1417-8. doi: 10.1136/annrheumdis-2016-209290. Epub 2016 Mar 25. Review. No abstract available.

28.

An Individual's Rate of Forgetting is Stable Over Time but Differs Across Materials.

Sense F, Behrens F, Meijer RR, van Rijn H.

Top Cogn Sci. 2016 Jan;8(1):305-21. doi: 10.1111/tops.12183. Epub 2016 Jan 8.

29.

[Do we still need clinical studies in rheumatology?].

Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H.

Z Rheumatol. 2016 Feb;75(1):4-10. doi: 10.1007/s00393-015-1687-x. German.

PMID:
26680367
30.

Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.

Behrens F, Koehm M, Arndt U, Wittig BM, Greger G, Thaçi D, Scharbatke E, Tony HP, Burkhardt H.

J Rheumatol. 2016 Mar;43(3):632-9. doi: 10.3899/jrheum.141596. Epub 2015 Dec 15.

31.

Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.

Köhm M, Burkhardt H, Behrens F.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S109-14. Epub 2015 Oct 15. Review.

PMID:
26472504
32.

Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, Barton A.

Nat Commun. 2015 Jul 6;6:7741. doi: 10.1038/ncomms8741. No abstract available.

33.

[Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence].

Köhm M, Behrens F.

Z Rheumatol. 2015 Jun;74(5):398-405. doi: 10.1007/s00393-014-1530-9. German.

PMID:
26085072
34.

PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.

Bowes J, Loehr S, Budu-Aggrey A, Uebe S, Bruce IN, Feletar M, Marzo-Ortega H, Helliwell P, Ryan AW, Kane D, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, Brown MA, Behrens F, Burkhardt H, McHugh N, Huffmeier U, Ho P, Reis A, Barton A.

Ann Rheum Dis. 2015 Oct;74(10):1882-5. doi: 10.1136/annrheumdis-2014-207187. Epub 2015 Apr 28.

35.

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger M, Kleinert S, Scharbatke EC, Gnann H, Behrens F, Wittig BM, Greger G, Tony HP.

Clin Exp Rheumatol. 2015 May-Jun;33(3):321-9. Epub 2015 Apr 14.

PMID:
25897681
36.

Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, Barton A.

Nat Commun. 2015 Feb 5;6:6046. doi: 10.1038/ncomms7046. Erratum in: Nat Commun. 2015;6:7741.

37.

Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.

Thaçi D, Behrens F, Greger G, Burkhardt H, Gnann H, Schopf R, Wittig BM.

Dermatology. 2015;230(3):213-21. doi: 10.1159/000371546. Epub 2015 Jan 27.

PMID:
25632852
38.

Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.

Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B.

Rheumatology (Oxford). 2015 May;54(5):915-26. doi: 10.1093/rheumatology/keu415. Epub 2014 Oct 27. Review.

PMID:
25349441
39.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H.

Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.

40.

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D.

J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.

PMID:
23981683
41.

Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?

Gramsch C, Göricke SL, Behrens F, Zimmer L, Schadendorf D, Krasny A, Forsting M, Schlamann MU.

Eur Radiol. 2013 Sep;23(9):2622-7. doi: 10.1007/s00330-013-2857-3. Epub 2013 May 14.

PMID:
23670820
42.

Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.

Behrens F, Tony HP, Alten R, Kleinert S, Scharbatke EC, Köhm M, Gnann H, Tams J, Greger G, Burkhardt H.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1608-16. doi: 10.1002/acr.22037.

43.

Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis.

Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, Pasutto F, Ekici AB, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Padyukov L, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A, Hüffmeier U.

Arthritis Rheum. 2013 May;65(5):1224-31. doi: 10.1002/art.37885.

44.

[Personalized medicine in cytokine-targeted therapy].

Behrens F, Köhm M.

Z Rheumatol. 2013 Feb;72(1):41-8. doi: 10.1007/s00393-011-0886-3. German.

PMID:
23392600
45.

Leflunomide in psoriatic arthritis: results from a large European prospective observational study.

Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A, Thaçi D, Burkhardt H.

Arthritis Care Res (Hoboken). 2013 Mar;65(3):464-70. doi: 10.1002/acr.21848.

46.

Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization.

Böhm B, Burkhardt H, Uebe S, Apel M, Behrens F, Reis A, Hüffmeier U.

Arthritis Res Ther. 2012 Apr 18;14(2):R84. doi: 10.1186/ar3807.

47.

[Diagnosis and therapy of early psoriatic arthritis].

Köhm M, Behrens F.

Z Rheumatol. 2012 Jan;71(1):46-52. doi: 10.1007/s00393-011-0896-1. German.

PMID:
22286355
48.

Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus.

Giardina E, Hüffmeier U, Ravindran J, Behrens F, Lepre T, McHugh NJ, Korendowych E, Burkhardt H, Novelli G, Reis A.

Arthritis Rheum. 2011 Dec;63(12):3801-6. doi: 10.1002/art.30591.

49.

Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement.

Abdulghani M, Al Sheik A, Alkhawajah M, Ammoury A, Behrens F, Benchikhi H, Benkaidali I, Doss N, El Gendy A, Mokhtar I, Odendaal D, Raboobee N, Thaçi D, Weiss R, Whitaker D.

J Int Med Res. 2011;39(5):1573-88. Review.

PMID:
22117959
50.

Increased levels of anti-glycan antibodies in patients with cystic fibrosis.

Hirche TO, Stein J, Hirche H, Hausmann J, Wagner TO, Behrens F, Schröder O.

Eur J Med Res. 2011 Sep 12;16(9):385-90.

Supplemental Content

Loading ...
Support Center